Every material Form 8-K Alector, Inc. has filed with the SEC since October 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alector reported third quarter 2026 collaboration revenue of $162.9 million, up from $3.3 million a year earlier, after recognizing remaining deferred revenue following GSK's July 6, 2026 termination notice. The company swung to net income of $124.6 million, or $1.11 per share, from a net loss of $34.7 million, and said it has funded operations into the second half of 2029 with the Genentech upfront payment and October offering proceeds.
Collaboration revenue was $162.9 million, versus $3.3 million, driven by recognition of remaining deferred revenue after GSK's July 6, 2026 termination notice.
Net income was $124.6 million, or $1.11 per share, compared with a net loss of $34.7 million, or $0.34 per share, a year earlier.
Genentech licensed AL050 with a $100 million upfront payment and eligibility for up to $1.17 billion in milestones plus tiered royalties.
Cash, cash equivalents and investments were $138.7 million at September 30, 2026; the October offering raised about $75.0 million gross.
Alector, Inc. agreed on October 15, 2026 to sell 36,600,000 new shares of common stock at $2.05 per share through underwriters Morgan Stanley and BTIG, with expected gross proceeds of $75,030,000 before underwriting discounts and offering expenses. The offering is expected to close on October 19, 2026, and the company plans to use the net proceeds for general corporate purposes, including research, development and manufacturing. Because the company is issuing new shares, existing shareholders will own a smaller percentage of the company after closing.
Pricing: 36,600,000 shares at $2.05 per share, a premium of about 7.3% over the October 15, 2026 closing price
Expected gross proceeds of $75,030,000 before underwriting discounts and offering expenses
Expected closing on or about October 19, 2026, subject to customary conditions
Underwriters are Morgan Stanley & Co. LLC and BTIG, LLC; the offering is made under an effective Form S-3 shelf registration
Alector's board approved a repricing of underwater employee stock options on October 13, 2026, resetting their exercise price to $1.87 per share, the closing price that day. The repricing includes options held by CEO Arnon Rosenthal and Chief Accounting Officer Grace Wong-Sarad, and employees who exercise before the one-year Retention Period ends must pay the original exercise price instead.
Eligible options with exercise prices above $1.87 held by current employees were repriced to $1.87 per share, effective October 13, 2026.
Approximately 4.05 million shares underlie all repriced options, which previously had exercise prices ranging from $6.48 to $33.11.
CEO Arnon Rosenthal holds options on 2,421,197 shares, and Chief Accounting Officer Grace Wong-Sarad holds options on 87,385 shares, both included in the repricing.
Exercises before the Retention Period ends, which runs up to one year, require payment of the original exercise price; expiration dates and vesting were not changed.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alector, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →